MSK Employee Spotlight | Dr. Ross Levine, Chief Scientific Officer (CSO) at MSK, was recently elected to the @theNAMedicine (NAM), one of the most respected distinctions in science and medicine. Dr. Levine’s research focuses on the genetic changes that drive myeloid malignancies, including myeloproliferative neoplasms and acute myeloid leukemia, and translating these discoveries into more effective treatments. As MSK’s CSO, he leads basic and translational research strategy, overseeing programs, centers, technology cores, and the financial and operational resources that support MSK’s research enterprise. Previously, Dr. Levine served as HOPP's first chief of the Molecular Cancer Medicine Service, inaugural Director of the Center for Hematologic Malignancies, and Senior Vice President for Translational Research at Memorial Hospital. He holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes. Join us in congratulating Dr. Levine in the comments below!